Based on various research, different cells are effective for improving the symptoms and paraclinical indicators of patients with chronic spinal cord injury (SCI). A big gap in front of researchers and doctors is to know the source, the number of cells required for injection, the delivery method, and the required complementary treatments. We extracted the desired data (number of cells, autologous or allogeneic source of cell extraction, delivery method, and complementary treatments) from 40 clinical trials, which checked and recorded 17 scores of symptoms and paraclinical indicators in at least two studies. The most common cells for improving 11 scores were bone marrow hematopoietic stem cell and bone marrow mesenchymal stem cell. The mean effect was more in bone marrow mesenchymal stem cell with plasma as the complementary treatment. Then the highest mean effect was in bone marrow hematopoietic stem cell therapy, with the complementary treatment being methylprednisolone. The cell number (106/kg), the source (autologous), and the delivery method (intrathecal) were similar in both cell types. No life-threatening consequences or death were recorded. This guideline helps researchers and doctors choose the appropriate cell therapy method for chronic SCI.
Impact Statement
This guide will help researchers and doctors to choose the appropriate source of cell therapy, the number of cells required for injection, the delivery method, and the required complementary treatments in chronic spinal cord injury.
Get full access to this article
View all access options for this article.
References
1.
KayyalM, JamaliN, AbolghasemiR, et al.Regenerative medicine therapies for chronic spinal cord injury, a systematic review of reviews for evidence-based medicine. Trauma Monthly, 2023; 28(2):748–760; doi: 10.30491/TM.2023.365004.1518
2.
YamazakiK, KawaboriM, SekiT, HoukinK. Clinical trials of stem cell treatment for spinal cord injury. Int J Mol Sci, 2020; 21(11):3994; doi: 10.3390/ijms21113994
3.
RibeiroBF, da CruzBC, de SousaBM, et al.Cell therapies for spinal cord injury: A review of the clinical trials and cell-type therapeutic potential. Brain, 2023; 146(7):2672–2693; doi: 10.1093/brain/awad047
4.
AbolghasemiR, Davoudi-MonfaredE, AllahyariF, et al.Systematic review of cell therapy efficacy in human chronic spinal cord injury. Tissue Eng Part B Rev, 2024; 30(2):254–269; doi: 10.1089/ten.teb.2023.0130
5.
Davoudi-MonfaredE, AbolghasemiR, AllahyariF, et al.Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis. Regen Ther, 2024; 27:381–397; doi: 10.1016/j.reth.2024.03.012
6.
VaqueroJ, ZuritaM, RicoMA, et al.; Neurological Cell Therapy Group From Puerta De Hierro-Majadahonda Hospital. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy, 2018; 20(6):796–805; doi: 10.1016/j.jcyt.2018.04.006
7.
VaqueroJ, ZuritaM, RicoMA, et al.; Neurological Cell Therapy Group. An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial. Cytotherapy, 2016; 18(8):1025–1036; doi: 10.1016/j.jcyt.2016.05.003
8.
VaqueroJ, ZuritaM, RicoMA, et al.; Neurological Cell Therapy Group. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy, 2017; 19(3):349–359; doi: 10.1016/j.jcyt.2016.12.002
9.
VaqueroJ, ZuritaM, RicoMA, et al.; Neurological Cell Therapy Group from Puerta de Hierro-Majadahonda Hospital. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy, 2018; 20(6):806–819; doi: 10.1016/j.jcyt.2018.03.032
10.
ShroffG. Human embryonic stem cell therapy in chronic spinal cord injury: A retrospective study. Clin Transl Sci, 2016; 9(3):168–175; doi: 10.1111/cts.12394
11.
ShroffG, GuptaR. Human embryonic stem cells in the treatment of patients with spinal cord injury. Ann Neurosci, 2015; 22(4):208–216; doi: 10.5214/ans.0972.7531.220404
12.
SykováE, HomolaA, MazanecR, et al.Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant, 2006; 15(8–9):675–687; doi: 10.3727/000000006783464381
13.
SharmaA, SaneH, GokulchandranN, et al.Role of autologous bone marrow mononuclear cells in chronic cervical spinal cord injury-a longterm follow up study. J Neurol Disord, 2013; 1(138):2; doi: 10.4172/2329-6895.1000138
14.
ChernykhER, StupakVV, MuradovGM, et al.Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. Bull Exp Biol Med, 2007; 143(4):543–547; doi: 10.1007/s10517-007-0175-y
15.
GeffnerLF, SantacruzP, IzurietaM, et al.Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: Comprehensive case studies. Cell Transplant, 2008; 17(12):1277–1293; doi: 10.3727/096368908787648074
16.
LimaC, Pratas-VitalJ, EscadaP, et al.Olfactory mucosa autografts in human spinal cord injury: A pilot clinical study. J Spinal Cord Med, 2006; 29(3):191–203; doi: 10.1080/10790268.2006.11753874
17.
LimaC, EscadaP, Pratas-VitalJ, et al.Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair, 2010; 24(1):10–22; doi: 10.1177/1545968309347685
18.
ChenL, HuangH, XiH, et al.A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries. Cell Transplantation, 2014; 23(Suppl 1):S35–S44; doi: 10.3727/096368914X685014
19.
KishkNA, GabrH, HamdyS, et al.Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair, 2010; 24(8):702–708; doi: 10.1177/1545968310369801
20.
El-KheirWA, GabrH, AwadMR, et al.Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant, 2014; 23(6):729–745; doi: 10.3727/096368913X664540
21.
Mackay-SimA, FeronF, CochraneJ, et al.Autologous olfactory ensheathing cell transplantation in human paraplegia: A 3-year clinical trial. Brain, 2008; 131(Pt 9):2376–2386; doi: 10.1093/brain/awn173
22.
TabakowP, JarmundowiczW, CzapigaB, et al.Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplant, 2013; 22(9):1591–1612; doi: 10.3727/096368912X663532
23.
WuJ, SunT, YeC, et al.Clinical observation of fetal Olfactory Ensheathing Glia Transplantation (OEGT) in patients with complete chronic spinal cord injury. Cell Transplantation, 2012; 21(Suppl 1):S33–S7; doi: 10.3727/096368912X633743
24.
WangS, LuJ, LiYA, et al.Autologous olfactory lamina propria transplantation for chronic spinal cord injury: Three-year follow-up outcomes from a prospective double-blinded clinical trial. Cell Transplant, 2016; 25(1):141–157; doi: 10.3727/096368915X688065
25.
SharmaA, GokulchandranN, ChopraG, et al.Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplantation, 2012; 21(Suppl 1):S79–S90; doi: 10.3727/096368912X633798
26.
SharmaA, GokulchandranN, SaneH, et al.Detailed analysis of the clinical effects of cell therapy for thoracolumbar spinal cord injury: An original study. JN, 2013; 1(1):13–22; doi: 10.2147/JN.S43712
27.
AlbuS, KumruH, CollR, et al.Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: A randomized controlled study. Cytotherapy, 2021; 23(2):146–156; doi: 10.1016/j.jcyt.2020.08.008
28.
YangY, PangM, DuC, et al.Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: A phase 1/2 pilot study. Cytotherapy, 2021; 23(1):57–64; doi: 10.1016/j.jcyt.2020.09.012
29.
ChengH, LiuX, HuaR, et al.Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. J Transl Med, 2014; 12(1):253–258; doi: 10.1186/s12967-014-0253-7
30.
OhSK, ChoiKH, YooJY, et al.A phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury. Neurosurgery, 2016; 78(3):436–447; discussion 447; doi: 10.1227/NEU.0000000000001056
31.
ParkJH, KimDY, SungIY, et al.Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery, 2012; 70(5):1238–1247; discussion 1247; doi: 10.1227/NEU.0b013e31824387f9
32.
ViswanathanC, ShettyP. Clinical safety and efficacy of autologous mesenchymal stem cells in spinal cord injury: A clinical trial report. Advances of Stem Cells, 2013; doi: 10.5171/2013.679731
33.
PalR, VenkataramanaNK, BansalA, et al.Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy, 2009; 11(7):897–911; doi: 10.3109/14653240903253857
34.
MovigliaGA, VarelaG, BrizuelaJA, et al.Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients. Spinal Cord, 2009; 47(6):499–503; doi: 10.1038/sc.2008.164
35.
MendonçaMV, LaroccaTF, de Freitas SouzaBS, et al.Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther, 2014; 5(6):126–121; doi: 10.1186/scrt516
36.
KumarAA, KumarSR, NarayananR, et al.Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data. Exp Clin Transplant, 2009; 7(4):241–248.
37.
JeonSR, ParkJH, LeeJH, et al.Treatment of spinal cord injury with bone marrow-derived, cultured autologous mesenchymal stem cells. Tissue Eng Regen Med, 2010; 7(3):316–322.
38.
DaiG, LiuX, ZhangZ, et al.Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res, 2013; 1533:73–79; doi: 10.1016/j.brainres.2013.08.016
39.
AttarA, AytenM, OzdemirM, et al.An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy, 2011; 13(1):54–60; doi: 10.3109/14653249.2010.510506
40.
DedaH, InciMC, KürekçiAE, et al.Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy, 2008; 10(6):565–574; doi: 10.1080/14653240802241797
41.
LeviAD, AndersonKD, OkonkwoDO, et al.Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma, 2019; 36(6):891–902; doi: 10.1089/neu.2018.5843
42.
ShinJC, KimKN, YooJ, et al.Clinical trial of human fetal brain-derived neural stem/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plast, 2015; 2015:630932; doi: 10.1155/2015/630932
43.
CurtA, HsiehJ, SchubertM, et al.Safety and preliminary efficacy of allogeneic neural stem cell transplantation in chronic spinal cord injury: A translational phase I/IIa trial. 2019; doi: 10.2139/ssrn.3335037
44.
BydonM, QuW, MoinuddinFM, et al.Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. Nature Communications, 2024; 15(1):2201; doi: 10.1038/s41467-024-46259-y
45.
TangQR, XueH, ZhangQ, et al.Evaluation of the clinical efficacy of stem cell transplantation in the treatment of spinal cord injury: A systematic review and meta-analysis. Cell Transplant, 2021; 30:9636897211067804; doi: 10.1177/09636897211067804
46.
Montoto-MeijideR, Meijide-FaíldeR, Díaz-PradoSM, et al.Mesenchymal stem cell therapy in traumatic spinal cord injury: A systematic review. Int J Mol Sci, 2023; 24(14):11719; doi: 10.3390/ijms241411719
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
